News & Comment
Cambridge-based biotech Acambis (ACM) saw its shares leap 37 per cent to 332.5p in early trading after its US subsidiary won a $428m (£355m) order to supply the US government with 155 million doses of smallpox vaccine. William Davidson reports.
Read
|
Recommendations
Acambis
HOLD 21/01/2008
Long thought of as a ‘bio-defence’ specialist, Acambis has five other major treatments in clinical stages for a range of infections, with a number expected to make progress in the coming year.
Read
Acambis
NO RECOMMENDATION 01/08/2001
Read
Acambis
NO RECOMMENDATION 28/06/2001
Read
Acambis
NO RECOMMENDATION 16/03/2001
Read
Acambis
NO RECOMMENDATION 12/02/2001
Read
Read
Read
Read
Read
Read
Read
|
Sector Articles
The markets' extreme volatility in the run-up to and then reality of war with Iraq has dominated both the headlines and the thoughts of City folk – putting the March results season somewhat into the shade.
Read
TechMARK has been marking time recently, despite the glut of results coming on to the market. At 1213.1, the index of the 100 biggest firms is only slightly up on what it was at the end of February.
Read
|
|
|
